Samsung Securities: "Samsung Epis Holdings faces next-year milestone gap and rising R&D burden… target price cut to ₩500,000"
Predicted impact: Low
Broker target price cut on milestone gap and higher R&D; opinion, not company news.
Samsung Epis Holdings삼성에피스홀딩스
0126Z0 · KOSPI · ₩0126Z0 · 삼성에피스홀딩스
₩307,000▼ ₩9,500 (3.00%)End-of-day · Oct 29, 2026 · End-of-day prices.
Price · 1Y −29.99%
- Market cap
- ₩7.6T
- Enterprise value
- ₩7.5T
- P/E
- 89.5×
- P/B
- 1.3×
- Dividend yield
- 0.0%
- ROE
- 1.4%
- Net margin
- 33.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−60.3% from the high
₩297,500Today: ₩301,500 – ₩320,000₩773,000
Returns
- 1W−6.4%
- 1M−9.6%
- 3M−12.0%
- 6M−43.5%
- YTD−58.7%
- 1Y—
- Volume today
- 38,458
- 1.1× the 20-day average
- Traded today
- ₩12B
- Listed shares
- 24,883,049
- EPS (12 months)
- ₩3,429
- Earnings yield 1.1%
AI research · InitiationSamsung Epis Holdings: Recently Listed Holding Company Trades Near 52-Week Low With Loss-Making OperationsThe data shows a recently listed holding company with a loss-making operating line, profitable bottom line, negative free cash flow and a share price close to its 52-week low.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 45 of 100 (50 is a normal day for this stock).
- SentimentNegativeNews: A broker cut its target price and warned of a milestone gap and higher R&D costs. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-7.5% over the last month; the price is below its 20-day average.
- News impactSome5 news items and filings in two weeks; 0 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 29: sell ₩259M at the close (2.1% of 20-day average trading value)
On its 22 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 9.2% of trading value and pointed the same way 17 of 22 times.
- -2× KODEX 200 Futures Inverse 2X −₩185M
- 2× KODEX Leverage −₩22M
- 2× TIGER 200IT Leverage −₩13M
- -1× KODEX Inverse −₩11M
- 2× TIGER Leverage −₩8.6M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 32 funds.
- KODEX 2000.2%
- TIGER 2000.2%
- KODEX 200TR0.2%
- KODEX Leverage2×0.2%
- RISE 2000.2%
- ACE 2000.2%
- KIWOOM 200TR0.2%
- PLUS 2000.2%
Estimated from the funds' index or underlying stock.
Futures and options
All stock futures →Futures (2026-11): 304,500
Basis −0.81% · implied rate −21.3%
Open interest 1,183 contracts
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
Samsung Epis Holdings stock overview
Samsung Epis Holdings (삼성에피스홀딩스, KRX: 0126Z0) is listed on KOSPI, in the Holding companies sector. Samsung Epis Holdings is a Korean holding company, regulated under the Monopoly Regulation and Fair Trade Act, that owns two subsidiaries: Samsung Bioepis, which develops and commercializes biosimilar drugs, and Epis NexLab, which focuses on next-generation bio technology platforms. Its shares closed at ₩307,000 on Oct 29, 2026, down 3.00% on the day, giving it a market value of ₩7.6T.
Key facts
- Market cap
- ₩7.6T
- Sector
- Holding companies
- Latest price change
- −3.00%
- As of
- Oct 29, 2026
- Main business
- Samsung Epis Holdings is a Korean holding company, regulated under the Monopoly Regulation and Fair Trade Act, that owns two subsidiaries: Samsung Bioepis, which develops and commercializes biosimilar drugs, and Epis NexLab, which focuses on next-generation bio technology platforms.
Quick answers about Samsung Epis Holdings
- What does Samsung Epis Holdings do?
- Samsung Epis Holdings is a Korean holding company, regulated under the Monopoly Regulation and Fair Trade Act, that owns two subsidiaries: Samsung Bioepis, which develops and commercializes biosimilar drugs, and Epis NexLab, which focuses on next-generation bio technology platforms. Samsung Bioepis has commercialized 11 biosimilar products globally, sells mainly through partner companies, and exports most of its revenue to markets including the United States, Europe, Canada, Australia, Brazil and Japan. It is also developing antibody-drug conjugate (ADC) drug candidates.
- What is the market cap of Samsung Epis Holdings?
- The market capitalisation of Samsung Epis Holdings was ₩7.6T at the close on Oct 29, 2026.
- Who are the largest shareholders of Samsung Epis Holdings?
- According to the latest official filings, the largest reported holders are Samsung C&T (74.32%, as of Nov 28, 2025); Samsung Electronics (31.22%, as of Nov 28, 2025); National Pension Service (5.70%, as of Apr 1, 2026).
- When is the next earnings report from Samsung Epis Holdings?
- Korean companies rarely announce results dates in advance. Based on when Samsung Epis Holdings filed the same report in past years, its next preliminary results is expected between Jan 26, 2027 and Oct 28, 2027.
- Does the National Pension Service own Samsung Epis Holdings?
- Yes. The National Pension Service held 5.70% of Samsung Epis Holdings shares as of Apr 1, 2026.
Company profile
Samsung Epis Holdings is a Korean holding company, regulated under the Monopoly Regulation and Fair Trade Act, that owns two subsidiaries: Samsung Bioepis, which develops and commercializes biosimilar drugs, and Epis NexLab, which focuses on next-generation bio technology platforms. Samsung Bioepis has commercialized 11 biosimilar products globally, sells mainly through partner companies, and exports most of its revenue to markets including the United States, Europe, Canada, Australia, Brazil and Japan. It is also developing antibody-drug conjugate (ADC) drug candidates.
Written by AI from the company's latest annual report.
- Korean name
- 삼성에피스홀딩스
- Sector
- Holding companies
- Themes
- Biosimilars
- Business group
- Samsung
- CEO
- 김경아
- Founded
- Nov 2025
- Listed
- Nov 2025
- Listed shares
- 24,883,049
- Fiscal year ends
- Month 12
- Website
- www.samsungepisholdings.com
Similar companies
- SK Square402340 · ₩126T₩953,000+3.47%
- KB Financial Group105560 · ₩56T₩156,800+1.82%
- Shinhan Financial Group055550 · ₩42T₩88,500+0.80%
- SK034730 · ₩39T₩535,000−0.93%
- Hana Financial Group086790 · ₩32T₩119,700+3.82%
- Woori Financial Group316140 · ₩23T₩30,800+3.01%
- Meritz Financial Group138040 · ₩22T₩131,400+6.40%
- HD Korea Shipbuilding & Offshore Engineering009540 · ₩16T₩233,000−3.52%
Recent news
Samsung Bioepis secures 10-year exclusive drug supply deal in Brazil
Predicted impact: Low
Brazil supply deal with value not disclosed; subsidiary-level impact likely small.
Recent filings
See all- Preliminary earnings (consolidated)Oct 28, 2026
- Preliminary earnings (consolidated)Oct 28, 2026
- Response to rumour or news reportOct 21, 2026
- Advance Notice of Earnings Results Disclosure (Informational Disclosure)Oct 14, 2026
- Change in largest shareholder's holdingsOct 6, 2026
Titles in Korean until English translations are added.
Also known as: Samsung Epis Holdings / 삼성에피스홀딩스 / 0126Z0 / KRX:0126Z0
Source: KRX statistical information